As of Aug 26
| +0.15 / +1.89%|
The 6 analysts offering 12-month price forecasts for Neogenomics Inc have a median target of 11.00, with a high estimate of 12.00 and a low estimate of 10.00. The median estimate represents a +36.31% increase from the last price of 8.07.
The current consensus among 7 polled investment analysts is to Buy stock in Neogenomics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.